Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Eosinophilic Esophagitis

Eosinophilic Esophagitis

Part of Esophageal Diseases

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Eosinophilic Esophagitis

34 trials tracked for Eosinophilic Esophagitis: 12 in phase 3 or 4 and 6 with published results. The most-cited published study has 556 citations.

34Trials tracked
12Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 4 Phase 3 8 Phase 2 11 Phase 1 1 Other / NA 10
  1. Phase 3 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed · 556 cited
  2. Phase 4 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed · 196 cited
  3. Phase 4 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed · 40 cited
  4. Phase 3 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Completed · 26 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Completed · 18 cited
  6. Phase 4 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis Completed · 5 cited
Show 28 more trials
  1. Phase 4 Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) Completed
  2. Phase 3 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed
  3. Phase 3 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed
  4. Phase 3 A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis Completed
  5. Phase 3 Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Completed
  6. Phase 3 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed
  7. Phase 2 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Completed
  8. Phase 2 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Completed
  9. Phase 2 A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis Completed
  10. Phase 2 Topical Steroid Treatment for Eosinophilic Esophagitis Completed
  11. Phase 2 Milk Patch for Eosinophilic Esophagitis Completed
  12. Phase 2 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) Completed
  13. Phase 2 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed
  14. Phase 2 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed
  15. Phase 2 Mepo for Eosinophilic Esophagitis (EoE) Study Completed
  16. Phase 2 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Completed
  17. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis Completed
  18. Phase 1 Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation Completed
  19. N/A Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma Completed
  20. N/A Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis Completed
  21. N/A Mucosal Impedance and Eosinophilic Esophagitis Completed
  22. N/A Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE) Completed
  23. N/A Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies Completed
  24. N/A Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) Completed
  25. N/A Cytosponge and Dietary Therapy in EoE Completed
  26. N/A Study to Image the Esophagus Using the OFDI Capsule Completed
  27. N/A Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis Completed
  28. N/A Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Eosinophilic Esophagitis: what the trials found

New evidence indicates that CC-93538 is associated with a significant reduction in mean Dysphagia Days at week 24 9 and a significantly higher percentage of patients achieving peak esophageal eosinophil counts of 6/Hpf compared to placebo at both week 24 and week 48 9. Additionally, CC-93538 is associated with new clinical data in Phase 3 trials 1.

Dupilumab has demonstrated significant efficacy in reducing peak esophageal intraepithelial eosinophil counts (p < 0.0001) and improving Dysphagia Symptom Questionnaire (DSQ) scores (p = 0.0004) 8. In a separate study, Dupilumab was associated with a statistically significant reduction in Straumann Dysphagia Instrument (SDI) scores at week 10 20.

Reslizumab is associated with significant reductions in peak esophageal eosinophil levels (p < 0.0001), physician global assessments of eosinophils (p = 0.0313), and predominant symptom assessments (p = 0.0062) 7. It also showed improvements in Child Health Questionnaire scores 12.

Lirentelimab (AK002) demonstrated a significant reduction in peak esophageal intraepithelial eosinophil counts at week 24 (p < 0.0001) 10. Fluticasone Propionate was associated with a significant reduction in pediatric symptom scores over 12 weeks (p = 0.04) 11, though it did not show a statistically significant difference in histologic remission rates compared to other groups 11. Losartan Potassium showed evidence of histologic remission and reduced peak eosinophil counts in small cohorts [18, 19].

Recent results — preliminary, needs further review

  • AQ280 Capsule showed no clinically significant abnormalities in blood pressure or pulse rate during Phase 1 testing 2.

For the clinician treating this condition

  • CC-93538 shows statistically significant improvements in both dysphagia duration and eosinophil count reduction compared to placebo 9.
  • Dupilumab is associated with significant reductions in intraepithelial eosinophils and improved patient-reported dysphagia scores [8, 20].
  • Reslizumab demonstrates significant clinical improvement across multiple metrics including eosinophil levels and physician assessments 7.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
H. pylori shows no overall link to pediatric asthma, but subgroup signals diverge
Allergy & Immunology Meta-analysis
H. pylori shows no overall link to pediatric asthma, but subgroup signals diverge Review of how stomach bacteria might affect childhood asthma and digestive health
This systematic review and meta-analysis examined associations between Helicobacter pylori infection and immune-mediated disorders in childr…
Experts looked at whether a common stomach infection affects kids with asthma or other digestive issues. The results were not clear.
Oct 19, 2026
Dupilumab and cendakimab show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis
Allergy & Immunology Sys. Review
Dupilumab and cendakimab show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis New data shows different treatments for eosinophilic esophagitis symptoms
This network meta-analysis evaluates various treatments for eosinophilic esophagitis in adolescents and adults. The analysis indicates that …
New research identifies specific medications that help improve swallowing difficulties for adults and teens with eosinophilic esophagitis.
Sep 1, 2026
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases
Nutrition & Obesity Medicine Sys. Review
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases Vitamin D's Role in Gut and Lung Health Examined
This narrative review synthesizes evidence on vitamin D deficiency and VDR expression across gastrointestinal and pulmonary conditions. The …
A review explores how vitamin D deficiency and VDR expression may influence digestive and respiratory diseases, but more research is needed.
Frontiers May 18, 2026
Meta-analysis finds 2.31% EoE incidence with food allergen immunotherapy, none with aeroallergen SLIT
Allergy & Immunology Meta-analysis
Meta-analysis finds 2.31% EoE incidence with food allergen immunotherapy, none with aeroallergen SLIT Study finds link between food allergy treatment and rare swallowing condition
A systematic review and meta-analysis of 17 studies in patients receiving allergen immunotherapy found the incidence of confirmed eosinophil…
Food allergy treatment linked to rare swallowing condition in 2.3% of patients receiving food desensitization, while airborne treatments sho…
Apr 2, 2026